Is IVERIC bio, Inc. (ISEE) a Buy, Sell, or Hold?
Enter your email address below for free access to our IVERIC bio, Inc. (ISEE) research center and poll results.
NASDAQ : ISEE
IVERIC bio, Inc.
$39.95 USD
$0.15 (0.38%)
- Volume
- 10.8M
- Average Volume
- 5.29M
- Market Capitalization
- $5.51B
- P/E Ratio
- -27.55
- Dividend Yield
- 0.00%
- Price Target
- $34.50
- Year High
- $39.99
- Year Low
- $9.39
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $18.63
| Source | Headline |
|---|
Get ISEE Insider Trade Alerts
Sign up for InvestorConsensus.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.
Market Data and Calendars
Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.
ISEE Price Target Summary
Last Month
$0.00
0 analystsLast Quarter
$0.00
0 analystsLast Year
$0.00
0 analystsAll Time
$32.75
4 analystsISEE Recent Analyst Grades
| Date | Analyst Firm | Action | Previous Grade | New Grade |
|---|---|---|---|---|
| 2023-05-08 | TD Cowen | Downgrade | Outperform | Perform |
| 2023-05-07 | TD Cowen | Downgrade | Outperform | Perform |
| 2023-05-04 | Baird | Downgrade | Outperform | Neutral |
| 2023-05-03 | UBS | Downgrade | Buy | Neutral |
| 2023-05-03 | Baird | Downgrade | Outperform | Neutral |
| 2023-05-02 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| 2023-05-02 | UBS | Downgrade | Buy | Neutral |
| 2023-05-01 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| 2023-05-01 | Wedbush | Downgrade | Outperform | Neutral |
| 2023-05-01 | Guggenheim | Downgrade | Buy | Neutral |
| 2023-04-30 | Guggenheim | Downgrade | Buy | Neutral |
| 2023-04-30 | Wedbush | Downgrade | Outperform | Neutral |
| 2023-04-25 | Morgan Stanley | Maintain | Overweight | Overweight |
| 2023-04-24 | Morgan Stanley | Maintain | Overweight | Overweight |
| 2023-04-03 | Wedbush | Maintain | Outperform | Outperform |
| 2023-03-02 | HC Wainwright & Co. | Maintain | Buy | Buy |
| 2023-02-21 | B. Riley Securities | Maintain | Neutral | Neutral |
| 2023-02-20 | B. Riley Securities | Maintain | Neutral | Neutral |
| 2023-02-17 | HC Wainwright & Co. | Maintain | Buy | Buy |
| 2022-11-10 | Jefferies | Downgrade | Buy | Hold |
| 2022-11-09 | Jefferies | Downgrade | Buy | Hold |
| 2022-11-04 | HC Wainwright & Co. | Maintain | Buy | Buy |
| 2022-11-03 | HC Wainwright & Co. | Maintain | Buy | Buy |
| 2022-09-08 | Stifel | Maintain | Buy | Buy |
| 2022-09-07 | Baird | Maintain | Outperform | Outperform |
| 2022-09-07 | Stifel | Maintain | Buy | Buy |
| 2022-09-07 | Guggenheim | Maintain | Buy | Buy |
| 2022-09-06 | B. Riley Securities | Downgrade | Neutral | Sell |
| 2022-09-06 | Guggenheim | Maintain | Buy | Buy |
| 2022-09-06 | Baird | Maintain | Outperform | Outperform |
| 2022-09-05 | B. Riley Securities | Downgrade | Neutral | Sell |
| 2022-08-02 | UBS | Maintain | Buy | Buy |
| 2022-07-07 | Morgan Stanley | Maintain | Overweight | Overweight |
| 2022-07-06 | Morgan Stanley | Maintain | Overweight | Overweight |
| 2022-06-08 | Guggenheim | Maintain | Buy | Buy |
| 2022-06-08 | B of A Securities | Maintain | Buy | Buy |
| 2022-05-12 | B. Riley Securities | Maintain | Neutral | Neutral |
| 2022-03-22 | Jefferies | Maintain | Buy | Buy |
| 2022-03-03 | Baird | Maintain | Outperform | Outperform |
| 2022-02-07 | Morgan Stanley | Maintain | Overweight | Overweight |
| 2021-11-10 | HC Wainwright & Co. | Maintain | Buy | Buy |
| 2021-11-09 | HC Wainwright & Co. | Maintain | Buy | Buy |
| 2021-09-10 | Credit Suisse | Maintain | Outperform | Outperform |
| 2021-09-10 | Stifel | Maintain | Buy | Buy |
| 2021-09-09 | Credit Suisse | Maintain | Outperform | Outperform |
| 2021-08-19 | HC Wainwright & Co. | Maintain | Buy | Buy |
| 2020-08-13 | Credit Suisse | Maintain | Outperform | Outperform |
| 2020-01-24 | Cowen & Co. | Maintain | Outperform | Outperform |
| 2020-01-07 | Wedbush | Maintain | Outperform | Outperform |
| 2018-03-19 | JP Morgan | Downgrade | Neutral | Underweight |
| 2018-02-28 | Chardan Capital | Maintain | Neutral | Neutral |
| 2016-12-13 | Goldman Sachs | Upgrade | Sell | Neutral |
| 2016-12-13 | Morgan Stanley | Downgrade | Overweight | Equal Weight |
| 2016-12-13 | Gabelli & Co. | Downgrade | Buy | Hold |
| 2016-12-12 | Citigroup | Downgrade | Buy | Neutral |
| 2016-12-12 | SunTrust Robinson Humphrey | Downgrade | Buy | Hold |
| 2016-12-12 | Chardan Capital | Downgrade | Buy | Neutral |
| 2016-12-12 | Barclays | Downgrade | Overweight | Equal Weight |
| 2016-12-12 | JP Morgan | Downgrade | Overweight | Neutral |
| 2016-12-12 | Cowen & Co. | Downgrade | Outperform | Perform |
| 2016-09-08 | JP Morgan | Maintain | Overweight | Overweight |
| 2016-08-19 | BTIG Research | Maintain | Buy | Buy |
| 2016-08-04 | Citigroup | Maintain | Buy | Buy |
| 2016-06-02 | JP Morgan | Upgrade | Neutral | Overweight |
| 2016-04-27 | Barclays | Maintain | Overweight | Overweight |
| 2016-01-07 | SunTrust Robinson Humphrey | Maintain | Buy | Buy |
| 2015-08-07 | Goldman Sachs | Downgrade | Neutral | Sell |
| 2015-08-03 | Leerink Swann | Maintain | Outperform | Outperform |
| 2015-07-07 | Cowen & Co. | Maintain | Outperform | Outperform |
| 2015-05-12 | Stifel Nicolaus | Maintain | Buy | Buy |
| 2015-02-24 | Stifel Nicolaus | Maintain | Buy | Buy |
| 2015-02-18 | Chardan Capital | Maintain | Buy | Buy |
| 2014-12-16 | JP Morgan | Maintain | Overweight | Overweight |
| 2014-11-12 | Stifel Nicolaus | Maintain | Buy | Buy |
| 2014-07-25 | Gabelli & Co. | Maintain | Buy | Buy |
| 2014-07-07 | Oppenheimer | Maintain | Outperform | Outperform |
| 2014-05-20 | JP Morgan | Maintain | Overweight | Overweight |
| 2014-04-22 | Morgan Stanley | Maintain | Overweight | Overweight |
| 2013-10-21 | Morgan Stanley | Maintain | Overweight | Overweight |
| 2013-10-21 | JP Morgan | Maintain | Overweight | Overweight |
| 2013-10-21 | Leerink Swann | Maintain | Outperform | Outperform |
| 2013-10-21 | Stifel Nicolaus | Maintain | Buy | Buy |